The European Commission has approved AKEEGA® (niraparib and abiraterone acetate) for patients with BRCA1/2-mutated metastatic hormone-sensitive prostate cancer, following Phase 3 data showing a significant delay in disease progression and an early survival benefit.
PADCEV (enfortumab vedotin) plus Keytruda has demonstrated significant improvements in event-free and overall survival in patients with muscle-invasive bladder cancer, regardless of cisplatin eligibility.
Testicular cancer, by nature, is one of the most aggressive solid organ tumours. It can spread to virtually every part of the body but commonly to lymph nodes,…
Prostate cancer in Europe: the statistics Prostate cancer is the most commonly diagnosed cancer in men and the third leading cause of cancer-related deaths among males in Europe.…
Testicular cancer is rare, but it’s the most common cancer in young men aged between 15 and 44. About 170 men are diagnosed with testicular cancer every year…
Urinary tract infections (UTIs) are one of the most common bacterial infections globally, affecting millions of people each year. It is estimated that UTIs account for over 150…
Comedians Danny Kehoe and Karl Spain Front Powerful New Campaign Urging Men to Pay Attention to Their Pee this Prostate Cancer Awareness Month The Marie Keating Foundation is…
BRCA stands for BReast CAncer gene. BRCA1 and BRCA2 are tumour suppressor genes which means that they stop the cells in our body from growing and dividing out…
Penile cancer is a rare male genital cancer which presents in older men in the 6th or 7th decades. However, the disease is not limited to the older…
The Dilemma of Identifying and Treating Life limiting Prostate Cancer: Prostate Check may be the future of Men’s cancer screening Background In February 2021, the European Commission (EC)…
You’re all caught up.
